NIVOLUMAB WITH AZACYTIDINE IN PEDIATRIC RELAPSED/REFRACTORY AML:PHASE I RESULTS FROM TACL CONSORTIUM

被引：0
|
作者：
Verma, Anupam [1 ]
Chi, Yueh-Yun [1 ]
Malvar, Jemily [1 ]
Lamble, Adam [1 ]
Chaudhury, Sonali [1 ]
Sung, Lillian [1 ]
Agarwal, Archana [1 ]
Liang, Gangning [1 ]
Sposto, Richard [1 ]
Leong, Roy [1 ]
Brown, Patrick [1 ]
Kaplan, Joel [1 ]
Schafer, Eric [1 ]
Slone, Tamra [1 ]
Pauly, Melinda [1 ]
Chang, Bill [1 ]
Stieglitz, Elliot [1 ]
Wayne, Alan [1 ]
Hijiya, Nobuko [1 ]
Bhoywani, Deepa [1 ]
机构：
[1] Therapeut Adv Childhood Leukemia & Lymphoma, Salt Lake City, UT USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
    Verma, Anupam
    Chi, Yueh-Yun
    Malvar, Jemily
    Lamble, Adam
    Chaudhury, Sonali
    Agarwal, Archana
    Li, Hong-Tao
    Liang, Gangning
    Leong, Roy
    Brown, Patrick A.
    Kaplan, Joel
    Schafer, Eric S.
    Slone, Tamra
    Pauly, Melinda
    Chang, Bill H.
    Stieglitz, Elliot
    Wayne, Alan S.
    Hijiya, Nobuko
    Bhojwani, Deepa
    CANCERS, 2024, 16 (03)
  • [2] Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium
    Pommert, Lauren
    Schafer, Eric S.
    Malvar, Jemily
    Gossai, Nathan
    Florendo, Ellynore
    Pulakanti, Kirthi
    Heimbruch, Katelyn
    Stelloh, Cary
    Chi, Yueh-Yun
    Sposto, Richard
    Rao, Sridhar
    Huynh, Van Thu
    Brown, Patrick
    Chang, Bill H.
    Colace, Susan, I
    Hermiston, Michelle L.
    Heym, Kenneth
    Hutchinson, Raymond J.
    Kaplan, Joel A.
    Mody, Rajen
    O'Brien, Tracey A.
    Place, Andrew E.
    Shaw, Peter H.
    Ziegler, David S.
    Wayne, Alan
    Bhojwani, Deepa
    Burke, Michael J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 613 - 622
  • [3] Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
    Daver, Naval Guastad
    Basu, Sreyashi
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias
    Hendrickson, Stephany
    Brandt, Mark
    Pierce, Sherry
    Gordon, Tauna
    Pemmaraju, Naveen
    Andreeff, Michael
    Ning, Jing
    Kornblau, Steven
    Kadia, Tapan M.
    Dinardo, Courtney Denton
    Konopleva, Marina
    Allison, James Patrick
    Kantarjian, Hagop M.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase I study of decitabine and rapamycin in relapsed/refractory AML
    Liesveld, Jane L.
    O'Dwyer, Kristen
    Walker, Alison
    Becker, Michael W.
    Ifthikharuddin, J. J.
    Mulford, Deborah
    Chen, Rui
    Bechelli, Jeremy
    Rosell, Karen
    Minhajuddin, Mohammed
    Jordan, Craig T.
    Phillips, Gordon L., II
    LEUKEMIA RESEARCH, 2013, 37 (12) : 1622 - 1627
  • [5] Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.
    Itzykson, Raphael
    Thepot, Sylvain
    Recher, Christian
    Delaunay, Jacques
    Quesnel, Bruno
    Dreyfus, Francois
    Koka, Anne Marfaing
    Vey, Norbert
    Stamatoullas, Aspasia
    Gyan, Emmanuel
    Cluzeau, Thomas
    Rousselot, Philippe
    Reman, Oumedaly
    Plantier, Isabelle
    Marolleau, Jean Pierre
    More, Pierre
    Wattel, Eric
    Visanica, Sorin
    Zerhouni, Chahinez
    Bordessoule, Dominique
    Ades, Lionel
    Fenaux, Pierre
    Gardin, Claude
    BLOOD, 2009, 114 (22) : 436 - 436
  • [6] Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias J.
    Assi, Rita
    Brandt, Mark
    Pierce, Sherry
    Gordon, Tauna
    Pemmaraju, Naveen
    Andreeff, Michael
    Ning, Jing
    Kornblau, Steven
    Kadia, Tapan
    Flores, Wilmer
    Matthews, Jairo
    DiNardo, Courtney D.
    Borthakur, Gautam
    Konopleva, Marina
    Allison, James
    Sharma, Padmanee
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [7] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Basu, S.
    Garcia-Manero, G.
    Cortes, J.
    Ravandi, F.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Gordon, T.
    Brandt, M.
    Pierce, S.
    Matthews, J.
    Kornblau, S.
    Flores, W.
    Konopleva, M.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [8] A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
    Bond, David A.
    Yildiz, Vedat
    Wei, Lai
    Alinari, Lapo
    William, Basem M.
    Brammer, Jonathan E.
    Christian, Beth A.
    Blum, Kristie A.
    Maddocks, Kami J.
    BLOOD, 2019, 134
  • [9] Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
    Armand, Philippe
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Halwani, Ahmad
    Millenson, Michael M.
    Schuster, Stephen J.
    Timmerman, John
    Borrello, Ivan
    Gutierrez, Martin
    Scott, Emma C.
    Cattry, Deepika
    Chapuy, Bjoern
    Ligon, Azra H.
    Rodig, Scott J.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Shipp, Margaret A.
    BLOOD, 2014, 124 (21)
  • [10] CLINICAL RELEVANCE OF CYTOGENETICS IN RELAPSED PEDIATRIC AML: RESULTS FROM THE INTERNATIONAL RANDOMISED PHASE III STUDY RELAPSED AML 2001/01
    Kaspers, Gertjan
    Zimmermann, M.
    Reinhardt, D.
    Gibson, Brenda
    Tamminga, R.
    Aleinikova, O.
    Armendariz, H.
    Dworzak, M.
    Ha, S.
    Hovi, L.
    Maschan, A.
    Baruchel, A.
    Bertrand, Yves
    Razzouk, B.
    Rizzari, C.
    Smisek, P.
    Smith, O.
    Stark, B.
    Creutzig, U.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 820 - 820
12345